Cyprumed specializes in innovative oral delivery solutions for peptides such as GLP-1 agonists and Biopharmaceutics Classification System injectable (BCS Class IV) drugs, offering superior tablet formulations for enhanced bioavailability. With its team of experts and network, and its proprietary delivery platform, Cyprumed is at the forefront of the oral drug delivery technology industry. Cyprumed enables the transformation of novel peptides and BCS IV compounds into high-quality oral drug products.
company data |
|
| employees: | <= 5 |
| legal form: | Gesellschaft mit beschränkter Haftung |
| commercial register number: | 429073s |
| founding date: | 2015 |
| Mitglied im Cluster: | |
export countries: |
|
| world wide | |
products and services: |
|
| Research & Development of oral drug delivery systems for peptides | |
contact information |
|
| street: | Kreidweg 27 |
| ZIP code: | 6416 |
| city: | Obsteig |
| country: | Österreich |
| phone: | +43 660 768 49 77 |
| email: | info@cyprumed.net |
| website: | https://www.cyprumed.net |
|
contact: |
Dr. Florian Föger |
| function: | CEO |
| phone: | +43 660 768 49 77 |
| email: | florian.foeger@cyprumed.net |
|
contact: |
Dr. Martin Werle MBA |
| function: | COO |
| phone: | +43 660 860 50 29 |
| email: | martin.werle@cyprumed.net |
-
competences and specialization
- oral drug delivery
- oral GLP-1 peptide
- Oral peptide delivery